Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient-associated risk factors for severe anemia in patients with advanced ovarian or breast cancer receiving olaparib monotherapy: A multicenter retrospective study.
Tashiro R, Kawazoe H, Mamishin K, Seto K, Udagawa R, Saito Y, Hashimoto H, Shimoi T, Yonemori K, Yonemura M, Terakado H, Kawasaki T, Furukawa T, Nakamura T. Tashiro R, et al. Among authors: shimoi t. Front Oncol. 2022 Oct 4;12:898150. doi: 10.3389/fonc.2022.898150. eCollection 2022. Front Oncol. 2022. PMID: 36267984 Free PMC article.
64Cu-DOTA-trastuzumab PET imaging for HER2-specific primary lesions of breast cancer.
Sasada S, Kurihara H, Kinoshita T, Yoshida M, Honda N, Shimoi T, Shimomura A, Yunokawa M, Yonemori K, Shimizu C, Hamada A, Kanayama Y, Watanabe Y, Fujiwara Y, Tamura K. Sasada S, et al. Among authors: shimoi t. Ann Oncol. 2017 Aug 1;28(8):2028-2029. doi: 10.1093/annonc/mdx227. Ann Oncol. 2017. PMID: 28505219 Free article. No abstract available.
Phase 1 dose-escalation study of single-agent veliparib in Japanese patients with advanced solid tumors.
Nishikawa T, Matsumoto K, Tamura K, Yoshida H, Imai Y, Miyasaka A, Onoe T, Yamaguchi S, Shimizu C, Yonemori K, Shimoi T, Yunokawa M, Xiong H, Nuthalapati S, Hashiba H, Kiriyama T, Leahy T, Komarnitsky P, Fujiwara K. Nishikawa T, et al. Among authors: shimoi t. Cancer Sci. 2017 Sep;108(9):1834-1842. doi: 10.1111/cas.13307. Epub 2017 Aug 5. Cancer Sci. 2017. PMID: 28665051 Free PMC article. Clinical Trial.
Feasibility of olanzapine, multi acting receptor targeted antipsychotic agent, for the prevention of emesis caused by continuous cisplatin- or ifosfamide-based chemotherapy.
Bun S, Yonemori K, Akagi T, Noguchi E, Shimoi T, Shimomura A, Yunokawa M, Shimizu C, Fujiwara Y, Makino Y, Hayashi Y, Tamura K. Bun S, et al. Among authors: shimoi t. Invest New Drugs. 2018 Feb;36(1):151-155. doi: 10.1007/s10637-017-0487-3. Epub 2017 Jul 21. Invest New Drugs. 2018. PMID: 28733700 Clinical Trial.
116 results